CRNX
Price
$52.08
Change
-$3.29 (-5.94%)
Updated
Dec 18, 04:59 PM (EDT)
89 days until earnings call
IGC
Price
$0.36
Change
-$0.01 (-2.70%)
Updated
Dec 18 closing price
55 days until earnings call
Ad is loading...

CRNX vs IGC

Header iconCRNX vs IGC Comparison
Open Charts CRNX vs IGCBanner chart's image
Crinetics Pharmaceuticals
Price$52.08
Change-$3.29 (-5.94%)
Volume$10.47K
CapitalizationN/A
IGC Pharma
Price$0.36
Change-$0.01 (-2.70%)
Volume$318.68K
CapitalizationN/A
CRNX vs IGC Comparison Chart
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. IGC commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Buy and IGC is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (CRNX: $52.09 vs. IGC: $0.36)
Brand notoriety: CRNX and IGC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 171% vs. IGC: 92%
Market capitalization -- CRNX: $5.13B vs. IGC: $27.88M
CRNX [@Biotechnology] is valued at $5.13B. IGC’s [@Biotechnology] market capitalization is $27.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 1 FA rating(s) are green whileIGC’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 1 green, 4 red.
  • IGC’s FA Score: 0 green, 5 red.
According to our system of comparison, both CRNX and IGC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 4 TA indicator(s) are bullish while IGC’s TA Score has 4 bullish TA indicator(s).

  • CRNX’s TA Score: 4 bullish, 6 bearish.
  • IGC’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both CRNX and IGC are a bad buy in the short-term.

Price Growth

CRNX (@Biotechnology) experienced а -13.40% price change this week, while IGC (@Biotechnology) price change was -6.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.11%. For the same industry, the average monthly price growth was -2.34%, and the average quarterly price growth was +0.25%.

Reported Earning Dates

CRNX is expected to report earnings on Mar 18, 2025.

IGC is expected to report earnings on Feb 12, 2025.

Industries' Descriptions

@Biotechnology (-7.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($5.14B) has a higher market cap than IGC($27.9M). CRNX YTD gains are higher at: 55.621 vs. IGC (32.488). IGC has higher annual earnings (EBITDA): -8.69M vs. CRNX (-304.51M). CRNX has more cash in the bank: 863M vs. IGC (1.55M). IGC has less debt than CRNX: IGC (304K) vs CRNX (52.5M). IGC has higher revenues than CRNX: IGC (1.18M) vs CRNX (1.04M).
CRNXIGCCRNX / IGC
Capitalization5.14B27.9M18,405%
EBITDA-304.51M-8.69M3,503%
Gain YTD55.62132.488171%
P/E RatioN/AN/A-
Revenue1.04M1.18M88%
Total Cash863M1.55M55,821%
Total Debt52.5M304K17,270%
FUNDAMENTALS RATINGS
CRNX vs IGC: Fundamental Ratings
CRNX
IGC
OUTLOOK RATING
1..100
1819
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
48
Fair valued
PROFIT vs RISK RATING
1..100
9100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
4448
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
3n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IGC's Valuation (48) in the Biotechnology industry is somewhat better than the same rating for CRNX (92) in the Pharmaceuticals Major industry. This means that IGC’s stock grew somewhat faster than CRNX’s over the last 12 months.

CRNX's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is significantly better than the same rating for IGC (100) in the Biotechnology industry. This means that CRNX’s stock grew significantly faster than IGC’s over the last 12 months.

CRNX's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as IGC (98) in the Biotechnology industry. This means that CRNX’s stock grew similarly to IGC’s over the last 12 months.

CRNX's Price Growth Rating (44) in the Pharmaceuticals Major industry is in the same range as IGC (48) in the Biotechnology industry. This means that CRNX’s stock grew similarly to IGC’s over the last 12 months.

CRNX's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as IGC (100) in the Biotechnology industry. This means that CRNX’s stock grew similarly to IGC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXIGC
RSI
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 6 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
80%
Bearish Trend 16 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
OCEN21.28N/A
N/A
NYLI Clean Oceans ETF
PLTM9.08N/A
-0.05%
GraniteShares Platinum Trust
PYLD26.11-0.02
-0.08%
PIMCO Multisector Bond Active ETF
IGOV39.45-0.11
-0.28%
iShares International Treasury Bond ETF
FVC38.04-0.36
-0.94%
First Trust Dorsey Wright Dynamic Foc 5

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XENE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+1.35%
XENE - CRNX
47%
Loosely correlated
-0.07%
ARWR - CRNX
47%
Loosely correlated
-0.45%
PGEN - CRNX
44%
Loosely correlated
+2.46%
RARE - CRNX
44%
Loosely correlated
-0.99%
ELVN - CRNX
44%
Loosely correlated
+3.48%
More

IGC and

Correlation & Price change

A.I.dvisor indicates that over the last year, IGC has been loosely correlated with TECX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if IGC jumps, then TECX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IGC
1D Price
Change %
IGC100%
+1.23%
TECX - IGC
37%
Loosely correlated
+6.76%
ANVS - IGC
30%
Poorly correlated
+2.20%
AMLX - IGC
30%
Poorly correlated
+2.39%
CRNX - IGC
28%
Poorly correlated
+1.35%
VTGN - IGC
27%
Poorly correlated
-2.02%
More